A Perspective - can copper complexes be developed as a novel class of therapeutics?

Although copper-ligand complexes appear to be promising as a new class of therapeutics{,} other than the family of copper(ii) coordination compounds referred to as casiopeinas these compounds have yet to reach the clinic for human use. The pharmaceutical challenges associated with developing copper-based therapeutics will be presented in this article along with a discussion of the potential for high-throughput chemistry{,} computer-aided drug design{,} and nanotechnology to address the development of this important class of drug candidates.